Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial (pages 1203–1216)
H. J. Eisen, J. Kobashigawa, R. C. Starling, D. F. Pauly, A. Kfoury, H. Ross, S.-S. Wang, B. Cantin, A. Van Bakel, G. Ewald, S. Hirt, H. Lehmkuhl, A. Keogh, M. Rinaldi, L. Potena, A. Zuckermann, G. Dong, C. Cornu-Artis and P. Lopez
Article first published online: 22 FEB 2013 | DOI: 10.1111/ajt.12181
In this study comparing cardiac transplant recipients receiving one of two doses of everolimus with reduced dose cyclosporine to patients receiving mycophenolate mofetil with standard dose cyclosporine, the authors find no effect on acute cellular rejection, modestly reduced renal function, and a reduction in the incidence and severity of lesions defined by intravascular ultrasound. See editorial by Mehra on page 1119.